Chancellor Financial Group WB’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.37M Buy
5,451
+14
+0.3% +$3.01K 0.85% 24
2026
Q1
$1.18M Buy
5,437
+53
+1% +$11.8K 0.84% 24
2025
Q4
$1.23M Buy
5,384
+10
+0.2% +$2.28K 0.83% 24
2025
Q3
$1.24M Buy
5,374
+11
+0.2% +$2.24K 0.88% 24
2025
Q2
$996K Buy
5,363
+158
+3% +$29.4K 0.77% 30
2025
Q1
$1.09M Sell
5,205
-318
-6% -$61.8K 0.9% 22
2024
Q4
$981K Buy
+5,523
New +$1.02M 0.79% 25

Other funds holding ABBV

Chancellor Financial Group WB's ABBV Position: Q2 2026 in Review

Chancellor Financial Group WB increased its AbbVie (ABBV) stake by 0.26% in Q2 2026, buying an estimated $3.01K and bringing the position to 5,451 shares worth $1.37M. The position accounts for 0.85% of the portfolio, ranked #24.

Chancellor Financial Group WB first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Chancellor Financial Group WB held 5,451 shares of AbbVie worth $1.37M as of Q2 2026.
  • Chancellor Financial Group WB bought 14 AbbVie shares in Q2 2026, an estimated $3.01K.
  • AbbVie made up 0.85% of Chancellor Financial Group WB's portfolio in Q2 2026, its #24 holding.
  • Chancellor Financial Group WB first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Chancellor Financial Group WB's 13F filing for Q2 2026, filed 10 Aug 2026.